{"doi":"10.3390/ijms24119708","title":"Masitinib Inhibits Hepatitis A Virus Replication","abstract":"The hepatitis A virus (HAV) infection causes acute hepatitis. HAV also induces acute liver failure or acute-on-chronic liver failure; however, no potent anti-HAV drugs are currently available in clinical situations. For anti-HAV drug screening, more convenient and useful models that mimic HAV replication are needed. In the present study, we established HuhT7-HAV/Luc cells, which are HuhT7 cells stably expressing the HAV HM175-18f genotype IB subgenomic replicon RNA harboring the firefly luciferase gene. This system was made by using a PiggyBac-based gene transfer system that introduces nonviral transposon DNA into mammalian cells. Then, we investigated whether 1134 US Food and Drug Administration (FDA)-approved drugs exhibited in vitro anti-HAV activity. We further demonstrated that treatment with tyrosine kinase inhibitor masitinib significantly reduced both HAV HM175-18f genotype IB replication and HAV HA11-1299 genotype IIIA replication. Masitinib also significantly inhibited HAV HM175 internal ribosomal entry-site (IRES) activity. In conclusion, HuhT7-HAV/Luc cells are adequate for anti-HAV drug screening, and masitinib may be useful for the treatment of severe HAV infection.","journal":"International Journal of Molecular Sciences","year":2023,"id":380909,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9569,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1107381,"name":"Toshikatsu Shibata","orcid":"0000-0003-3235-4893","position":1,"is_corresponding":false},{"id":615986,"name":"Mitsuhiko Moriyama","orcid":"0000-0002-4617-508X","position":2,"is_corresponding":false},{"id":1107382,"name":"Hirofumi Kogure","orcid":"0000-0002-2355-7309","position":3,"is_corresponding":false},{"id":609998,"name":"Asuka Hirai-Yuki","orcid":"0000-0002-1218-8333","position":4,"is_corresponding":false},{"id":230990,"name":"Hiroaki Okamoto","orcid":"0000-0003-0827-0964","position":5,"is_corresponding":false},{"id":748367,"name":"Tatsuo Kanda","orcid":"0000-0002-1654-5385","position":6,"is_corresponding":false},{"id":895972,"name":"Reina Sasaki","orcid":"0000-0003-2681-0776","position":0,"is_corresponding":true}],"reference_count":53,"raw_metadata":null,"created_at":"2026-07-19T01:17:04.905707Z","pmid":"37298659","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}